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1. Introduction
Diagnostic methods for the detection of HPV should increase standardization and reproduci‐
bility due to two significant events in the future: the epidemiological monitoring changes in a
vaccinated population and the involvement of HPV in tumors of other anatomical sites.
It will be necessary to diagnose HPV in processes other than cervical cancer, and we refer not
only to their involvement in tumors with a demonstrated relationship, as in the anal region,
but also to other locations in which their participation is suggested, as in the oropharyngeal
tumors. Standardization in the collection and sample processing will be crucial in order to
achieve accurate results involving an aid in the diagnosis and prognosis of these processes and
their possible prevention.
However, the future challenge will be presented with the changes caused by the vaccination
campaigns and their influence on the prevalence of cytological abnormalities and screening
programs that will need to be designed according to the new status. There are already
published results showing a decrease in the incidence of HPV in young women vaccinated
Australia and confirm the estimates of predictive models [1].
Vaccination impact monitoring requires a multidisciplinary collaboration with technical and
information support adequate to provide significant evidence to justify changes in health
measures. However, screening should remain as an important strategy in cervical cancer
control in both vaccinated and unvaccinated people. The reduction in incidence in young
women after mass vaccination of adolescents together with greater range in controls and
improved sensitivity of HPV testing draws a picture with attractive screening programs more
efficient and cost effective in disease control.
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The availability of sensitive diagnostic assays for HPV, reproducible and cost effectively will
be critical in the monitoring of current vaccines and the design and implementation of
vaccination programs. The HPV vaccine offers a unique opportunity to fight against cancer
and diseases associated with HPV infection.
2. HPV epidemiology: The changes coming
Although the risk of cervical cancer was long known to be associated with risky sexual
behavior in both the woman and her partner, it was not until around 3 decades ago that HPV
was identified the likely culprit by Dr. Zur Hausen, whose work in cervical cancer won him
the Nobel Prize. The development of superior molecular techniques advanced the field rapidly
cementing the association between HPV and cervical cancer. This finding quickly led scientists
to examine HPV's association with other anogenital cancers in women including vulvar,
vaginal and anal cancers and in men, penile and anal cancers [2]. Most recently, oropharyngeal
cancers have joined the list of HPV-associated cancers. Although HPV was found to be
associated with these other anogenital cancers, most of the work continues to focus on cervical
cancers since it remains 20 times more common than any of the other HPV-associated cancers.
This phenomenon is likely due to the vulnerability of the cervix to HPV. Although the
mechanisms are not well understood, the transformation zone (TZ) is likely one of the most
vulnerable epithelia to HPV's carcinogenic powers [3]. The TZ change of columnar epithelium
to stratified epithelium Mullerian urogenital area in the ectocervix. In the puberty columnar
epithelium differentiates into stratified squamous epithelium. Metaplastic tissue is more
vulnerable to HPV because its thickness to the basal layer is smaller and the virus requires
cells in differentiation state for their survival, which is accelerated in metaplastic tissues [4]. It
is likely that this metaplastic tissue supports viral persistence which is essential for cancer
development. Interestingly metaplastic tissue is also found in the anal and tonsillar tissue.
According to a recent meta-analysis that included data from more than 1 million women in 59
countries, the prevalence of genital HPV infection among those with normal cytology ranges
from 1.6% to 41.9% [5]. The estimated average global prevalence of HPV in this particular study
was 11.7%. This study, along with others [6], reported an interesting trend in the female age-
specific distribution of HPV whereby there is a first peak at younger ages (< 25 years) in all
regions; and in the Americas, Africa and Europe, a clear second peak among individuals 45
years or older. The first peak, which comes shortly after sexual debut for most women, is
generally attributed to higher levels of sexual activity with multiple partners and low viral
immunity. After the first peak, a consistent age-related decline in HPV prevalence has been
documented in numerous epidemiological studies. Although the reason for the smaller second
peak at middle age still remains unclear, possible explanations include immunosenescence,
hormonal changes prior to menopause, changes in male/female sexual behavior, cohort effects,
or perhaps higher rates of HPV persistence at older ages [7]. However, new sexual exposures
and latent reactivation are often invoked as explanation for the second peak of HPV prevalence
observed in older women, particularly in Latin America [6]. Studies in humans are unable to
directly demonstrate establishment of latency and induction of reactivation from the latent
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state. However, animal models of papillomavirus infection have provided sufficient experi‐
mental evidence for papillomavirus latency [8]. HPV infects basal epithelial cells at sites of
microtrauma, likely a normal consequence of sexual intercourse. Infected basal cells induced
to differentiate to fill the wound will result in active papillomavirus infection. A few infected
basal stem cells will retain HPV, but do not differentiate, and these infected cells are unlikely
to be sampled using standard exfoliative techniques employed in most epidemiologic studies,
which sample only the surface epithelium. Thus, HPV in a basal stem cell may remain
undetectable until triggered to differentiate by undetermined stimuli such as wound repair
and hormonal regulation [9]. With high cellular turnover in the cervical epithelium, one may
expect relatively constant detection of HPV in this model. However, it is likely that a reacti‐
vated infection subsequent to latently infected stem cell differentiation is immediately
recognized and brought under control by a functional memory immune response resulting in
very short duration of active infection. This model would be consistent with the increase in
new HPV DNA detection immediately following memory T cell depletion in acute HIV and
in sexually abstinent women with chronic HIV infection [10, 11]. The relatively lower rates of
recurrent HPV DNA detection in healthy populations suggests that the normal immune
response is able to retain recurrence, but that background reactivation is common and likely
associated with short duration of detectable viral DNA [12].
Among sexually active males, genital HPV infection is also very common; however, prevalence
varies widely depending on geographic region, risk group, anatomical site, sampling method,
and HPV testing methodology [13, 14]. In a recent systematic review, Smith et al [15] estimated
HPV prevalence to be between 1% and 84% in low-risk sexually active men, and between 2%
and 93% in high risk men. HPV infection declines substantially after about 30 years of age, The
prevalence of HPV infection in males generally remains constant or declines only slightly with
age after peak prevalence. One possible explanation for this is that men experience a higher
rate of reinfection compared to women. Anal cancer is very rare in the general population, but
much more common in well defined, high-risk populations, including women with a previous
cervical precancer, men having sex with men (MSM), and immune-compromised individuals.
Infection with carcinogenic human papillomavirus (HPV) has been increasingly recognised to
cause anal cancer and Machalek et al [16] recorded a prevalence of high-risk anal HPV in HIV-
positive MSM of 73.5%.
In 1995, the International Agency for Research on Cancer (IARC) first classified HPV types 16
and 18 as carcinogenic to humans, but based on more recent evidence, the list of carcinogenic
HPV types has been expanded to include a total of 13 mucosotropic anogenital HPV types as
being definite or probable carcinogens (grade 1 or 2a) based on their frequent association with
invasive cervical cancer (ICC) and cervical intraepithelial neoplasia (CIN) [17]. The oncogenic
types (mostly HPV 16) are also causally implicated in other cancers, including penile, anal,
vulvar and vaginal cancers [18, 19]. The remaining genital types (e.g., HPV types 6, 11, 42, 43,
44 and some rarer types) are considered to be of low or no oncogenic risk [20]. However, these
types may cause subclinical and clinically visible benign lesions known as flat and acuminate
condylomata, respectively.
HPV Diagnosis in Vaccination Era
http://dx.doi.org/10.5772/55818
59
In descending order, the most common HPV types implicated in cervical cancer globally are:
16, 18, 58, 33, 45, 31, 52, 35, 59, 39, 51 and 56 [21]. HPV types 16 and 18 are the most dominant
types implicated in cervical cancer in all continents, being responsible for ~ 70% of ICC cases
globally. In many studies, estimating the fraction of cervical cancer cases attributable to the
different HPV types is difficult due to the high prevalence of multiple type infections. For
example, a recent meta-analysis estimated the prevalence of co-infection (≥ 2 HPV types) in
tumor specimens at 15.7% [21]. Other recent meta-analyses and cross sectional studies
evaluating the worldwide distribution of HPV infections consistently reveal the same HPV
prevalence patterns [5, 22]. This widespread circulation of HR-HPV types strengthens the
potential for a phenomenon known as type-replacement, i.e., an increase in other non-vaccine
genotypes following HPV vaccination. However, based on evidence that HPVs evolve very
slowly and that HPV types do not normally compete with one another during natural infection
[23-25], it is still unlikely that some other HPV type(s) will evolve to fill the niche currently
occupied by vaccine target types. Furthermore, phase III trials evaluating both bivalent and
quadrivalent vaccines indicate partial cross-type protection (cross-immunity) against many
phylogenetically related HPV types [26-28], suggesting that the benefit from vaccination may
be even greater than expected.
Infection of the oral cavity with high risk HPV is also now recognized as an important cause
of oral and oropharyngeal cancers [29]. However, unlike cervical cancer in which 100% of cases
are attributable to infection with HPV, only 25–35% of these cancers are attributable to HPV
[2, 30]; the major risk factors being alcohol and tobacco use. Among cases of oral/oropharyngeal
cancer linked to HPV infection, HPV 16 is by far the most common type detected in tumor
specimens [31, 32]. Based on evaluation of risk factor profiles for cancers of the head and neck,
comparing HPV 16-positive and HPV 16-negative cases, some researchers have decided that
these should actually be considered distinct cancers [33]. In their study, sexual behavior (but
not alcohol or tobacco use) was an important predictor of head and neck cancers among HPV
16-positive subjects, meanwhile the opposite was observed for HPV 16-negative subjects.
HPV 16 is the most common in all the HPV associated anogenital and oropharyngeal cancers
therefore the HPV vaccines currently on the market are likely to make a significant impact on
all these cancers in women and in men. In contrast, the role of HPV in penile cancers is less
understood. Trauma and inflammation appear to be important risks suggesting that tissue
damage and/or repair processes play a role in cancer development [34]. The natural history of
HPV in the penis is also not well described. Although there is a histologic equivalent of the
precancerous CIN 3 found in men, referred to as penile intraepithelial neoplasia (PIN), nothing
is known about the natural history of these lesions and whether they have the same potential
as CIN 3 (~ 12%) to progress to invasive cancer. One intriguing observation is that the penile
cancer has a much lower prevalence than cervical cancer and yet the prevalence of HPV is
much higher in the genitals of men than what is observed in women. Across all ages, HPV is
found 2–4 times more common in the genital area of men than seen in women and the decline
observed with age in women is not seen in men with similar prevalence across all ages. In
contrast, the natural history of HPV in anogenital area in men behaves similar to HPV in
women [35] in that HPV appears to be rapidly cleared so by 6–8 months, most infections are
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undetected. These observations and the fact that antibodies to HPV are less common in men
than in women suggest that most infections in men are relatively superficial and clearance is
likely directed by local innate immune responses, but not by memory immune responses [36].
Since men do not appear to develop adequate HPV specific immune responses, they are not
protected from re-infection. This is another argument for HPV vaccination in men. It may be
that sexually active males would benefit from vaccination. Benefits would include prevention
of penile, anal and oropharyngeal cancers and prevention of infections would, in theory, also
benefit women [37].
After breast and colorectal cancer, cervical cancer is the 3rd leading cancer site worldwide
irrespective of gender and second among women. In 2008, there were an estimated 530,000
cases and 270,000 deaths attributed to cervical cancer, with 86% of cases and 88% of deaths
occurring in developing countries [38]. In these developing countries, the age-standardized
incidence rate (ASIR) and age-standardized mortality rate (ASMR) were 18 and 10 per 100,000
women, respectively; whereas in more developed countries, the ASIR and ASMR were 9 and
3 per 100,000 women, respectively. Globally, incidence of ICC ranges from < 3 to > 50 cases per
100,000 women for low- and high-burden countries, respectively. These differences between
countries are believed to reflect protection from screening, and variance in exposure to HPV
and other cofactors like smoking and oral contraceptive use, and other sexually transmitted
infections such as human immunodeficiency virus [38].
The global burden of other HPV related cancers is also substantial. Worldwide, approximately
97,215 cases of non-cervical cancers for which HPV infection may be an etiologic factor are
diagnosed annually; roughly 50,780 in men (520 penile, 26,775 oropharyngeal and 13,485 anal
cancers) and 46,435 in women (25,600 vaginal/vulvar, 6048 oropharyngeal and 14,787 anal
cancers) [39]. However, it is important to recognize that not all of these cases are attributable
to HPV and that these estimates represent the upper limit for the annual burden of cancers
caused by HPV. only a quarter of oropharyngeal cancers are attributable to HPV; meanwhile
approximately 90% of anal cancers, and 40% of penile, vaginal or vulvar cancers are attribut‐
able to the virus. Although there is some evidence implicating HPV with several other cancers
(e.g., lung, colon, ovary, breast, prostate, urinary bladder, esophageal and nasal/sinonasal
cancers), current molecular and epidemiological data are sparse and do not yet support a
causal role for HPV in the etiology of these cancers [30, 40-42]. The role of HPV in the causation
of esophageal squamous cell carcinoma is unclear.
Globally, HPV accounts for roughly 5.2% of the total cancer burden — the highest among all
infectious agents. However, as may be expected, the distribution varies considerably according
to country development status, where HPV accounts for approximately 7.7% and 2.2% of all
cancer cases in developing and developed countries, respectively [42].
3. Screening methods for detect HPV infection
HPV cannot be cultured in conventional cell cultures. Other classical direct virological
diagnostic techniques, such as immunohistochemistry, lack the sensitivity as well as specificity
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for the routine detection of HPV. Serological assays for the detection of anti-HPV antibodies
have only limited analytical accuracy and their possible clinical utility is currently unresolved.
Consequently, all HPV tests currently in diagnostic use rely, on the detection of HPV nucleic
acids in clinical specimens.
Having relied on cervical cytology effectively for several decades, primary human papillo‐
mavirus (HPV) testing is increasingly and widely recognised as the means to deliver effective
cervical screening and the prevention of cervical cancer. Despite differences in the interven‐
tions amongst the main primary screening studies [43-46], the key message seems to be clear
and consistent: a primary HPV test will increase the sensitivity for detecting cervical intraepi‐
thelial neoplasia, grade 2+ (CIN2+), compared with cytology, and will allow the screening interval
to be extended with fewer life-time tests for women. Conventional cytology-based screening
is very effective in reducing cervical cancer when delivered in well-managed programmes
with high population coverage and robust quality assurance, but is costly in terms of work‐
force, finance and infrastructure. These programmes will be more difficult to sustain with
lower detection rates of abnormalities in HPV-immunised populations. Yet cervical screening
needs to sit alongside HPV immunisation to optimise cancer prevention. Screening pro‐
grammes will differ between different resource settings: e.g. introducing basic screening where
no previous programme has existed in low- or medium-resource settings, or providing more
clinically effective prevention in highly resourced countries with organised or opportunistic
screening. In protocols of prevention and treatment of cervical cancer involved, in addition to
cytology and HPV detection, other diagnostic tools such as colposcopy, histological categori‐
zation and use of new biomarkers, with the correct risk stratification parameter that must be
used to choose the appropriate procedures in the different phases of the clinical process:
screening, triage, diagnosis and treatment [47].
Screening, defined as the preventive activity that can diagnose the disease in healthy popula‐
tion a priori, should have as target detecting cervical intraepithelial neoplasia grade 3 (CIN3),
or being even stricter CIN2, histological stages of the disease are even preventable. Screening
by cervical cytology detects only 50-60% of cases of CIN3, including cytological revisions very
close in time. The analytical sensitivity of the detection of HPV DNA in exfoliated cells is much
higher, above 90%, but the clinical specificity is low because of virological diagnostic predicts
non persistence, necessary to cause the development of cancer. This limitation is accentuated
in young women with a good chance of getting an HPV infection self-limited. However, the
negative predictive value of HPV testing is very high and would, in patients free of viruses
could increase the periods between two revisions in years. Using both techniques simultane‐
ously (cytology + HPV), as has been done in some trial cohort (Northern California Kaiser
Permanent), increases the control intervals to three years with good results. Implementation
of HPV DNA testing in cervical screening leads to earlier detection of clinically relevant CIN
grade 2 or worse, which when adequately treated, improves protection against CIN grade 3
or worse and cervical cancer. Early detection of high-grade cervical legions caused by HPV16
was a major component of this benefit [48].
The costs are reduced in the triage by using a technique followed by another in accordance
with the results of the first. The cytology followed by HPV testing has been used but as already
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discussed the problems of the low sensitivity of cytology and uncertain cytology triage
(ASCUS) or low-risk lesions (LSIL) can lead to positive HPV tests with unknown clinical
significance. However, the benefits of the HPV test result prior cytology have been demon‐
strated [49]. Currently there are proposals to make the detection of HPV followed by cytology,
which has the best results of clinical sensitivity, reducing costs to distance the negative control
women but also may increase if performed in populations with a high incidence of infection,
as in young women [50]. Hence, several protocols established older than 30-35 years for a
suitable cost-effectiveness. It remains to determine the usefulness of combining HPV screening
combined with a new biomarkers triage as detection of HPV mRNA, p16-INK, and other
histological progression markers (Ki-67, MCM2 and TOP2A).
This scenario has increased the range of methods and technologies for the diagnosis of HPV
in clinical samples, whether exfoliated cells or biopsy, even paraffin. Extraction procedures
of nucleic acids, methods of viral genome detection and automation necessary for a determi‐
nation which is becoming routine laboratories have acquired high levels of complexity for
the most suitable choice [51]. The commercially available tests can be systematized in five
groups [52]: 1) screening assays based on the detection of HPV DNA of high risk, which
includes  hybrid  capture  as  the  reference  method  because  of  the  enormous  experience
gathered in previous studies, amplification using probes invader and PCR procedures, 2)
similar screening tests for the detection of DNA of high-risk HPV concurrent determina‐
tions of genotypes or reflex HPV-16 and HPV-18 genotypes whose infection is  a risk of
developing cancer than other genotypes too, 3) genotyping assays based on HPV PCR using
various technologies: reverse hybridization, microarray, array and RFLP suspension, which
joins the pyrosequencing and other methods of mass sequencing, 4) based screening assays
for the quantification of mRNA expression of E6/E7 high-risk HPVs, with the added value of
its  utility  as  a  marker  of  progression,  and  5  )  in  situ  hybridization,  available  but  with
limitations because of lower sensitivity.
4. HPV-DNA screening methods
High-risk HPV-DNA-based screening assays represent a group of qualitative or semi-
quantitative multiplex assays in which the DNA of the targeted HPV types is detected using
mixtures of probes (probe cocktails) for several HPV types with similar clinical characteristics.
None of the assays from this group allow the exact determination of HPV type(s) present in a
clinical specimen, but rather express the results of the tested group of HPV types as positive
or negative. Until recently, such an approach has been widely accepted by the HPV community
as the best way to present the results of hr-HPV testing to clinicians involved in primary
screening for cervical carcinoma and management of patients with cervical intraepithelial
neoplasia (CIN). The Hybrid Capture 2 (HC2) HPV DNA Test, originally developed by Digene
Corporation (Gaithersburg, MD, USA) in 1997 and currently marketed by Qiagen, has been
the most important HPV diagnostic assay for the last decade and is still the most frequently
used diagnostic HPV test worldwide [53]. The main problems of the current version of HC2
are: analytical inaccuracy due to the cross-reactivity of its probe cocktails with untargeted HPV
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types; and lack of internal control to evaluate specimen adequacy or the presence of potentially
interfering substances. In order to resolve the current problems of analytical inaccuracy and
to improve HC2 throughput, a next-generation diagnostic system has been developed [54].
Significant improvements have been engineered into the next-generation hybrid-capture
system, which builds on the current advantages of the FDA-approved HPV screening tech‐
nology, HC2. Central to the improved chemistry in the NextGen assay on the QIAensemble
automated system is the new collection medium, DCM [54].
The Amplicor HPV Test (Amplicor; Roche Molecular Systems, Branchburg, NJ, USA), launched
on the European market in 2004, is a qualitative PCR-based test designed to detect the same 13
HPV types as HC2: HPV-16, HPV-18, HPV-31, HPV-33, HPV-35, HPV-39, HPV-45, HPV-51,
HPV-52, HPV-56, HPV-58, HPV-59 and HPV-68. Similarly to HC2, Amplicor expresses the results
of the tested group of hr-HPV types as positive or negative. Amplicor is based on standard PCR
amplification and detection of PCR products on microwell plates [55]. The Cervista HPV HR
Test (Cervista; Hologic) is another FDA-approved signal amplification-based qualitative test
for the routine detection of 14 HPVs. In March 2009, the FDA approved Cervista for two
indications: to screen patients with ASC-US cervical cytology results to determine the need for
referral to colposcopy; and to be used adjunctively with cervical cytology to screen women 30
years of age and older to assess the presence or absence of hr-HPV types [56]. In contrast to HC2,
Cervista is based on the Invader chemistry, a signal amplification method for detecting specific
nucleic acid sequences. With support from the Bill and Melinda Gates Foundation, a careHPV
Test (Qiagen), based on simplified HC2 technology, has been recently developed to detect the
13 HPV types included in the original HC2 plus HPV-66, in approximately 3 h. Such rapid, simple
and affordable HPV tests, whereby results can be given to a patient within the same visit, are
anticipated to have the greatest impact in countries in which cervical cancer screening pro‐
grams do not exist or in countries in which substantial loss to follow-up impairs the effective‐
ness of cervical cancer screening programs [57].
5. HPV-DNA screening methods with concurrent or reflex HPV-16 &
HPV-18 genotyping
Reflex HR HPV DNA testing is now recognized as a cost-effective strategy to refer women
with an ASC-US cytology for colposcopy [58, 59]. High-risk HPV-DNA-based screening assays
with individual or pooled HPV-16 and HPV-18 genotyping are a group of novel HPV assays
in which qualitative detection of 13–14 HPV types is combined with concurrent or reflex
HPV-16 and HPV-18 genotyping. The Abbott RealTime High Risk HPV test (RealTime; Abbott
Molecular, Des Plaines, IL, USA) is a real-time PCR assay based on concurrent individual
genotyping for HPV-16 and HPV-18 and pooled detection of 12 other HPVs: HPV-31, HPV-33,
HPV-35, HPV-39, HPV-45, HPV-51, HPV-52, HPV-56, HPV-58, HPV-59, HPV-66 and HPV-68.
Amplification of human β-globin is used as an internal control. The assay was launched on
the European market in January 2009. RealTime is performed on the m2000rt real-time PCR
instrument (Abbott Molecular) using a modified GP5+/GP6+ primer mix consisting of three
forward and two reverse primers [60]. Analytical sensitivity of RealTime was comparable to
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that of HC2 (97.6% vs 95.1%), whereas RealTime demonstrated significantly higher analytical
specificity compared with HC2 [61, 62].
The cobas 4800 HPV Test (Roche Molecular Diagnostics, Pleasanton, CA, USA) is a real-time
PCR assay based on concurrent individual genotyping for HPV-16 and HPV-18 and pooled
detection of 12 other HPVs: HPV-31, HPV-33, HPV-35, HPV-39, HPV-45, HPV-51, HPV-52,
HPV-56, HPV-58, HPV-59, HPV-66 and HPV-68 [63-65]. An excellent agreement (>93%) was
obtained between cobas 4800 HPV and HC2 or Linear Array (LA) for the detection of HR HPV
DNA in CIN [66]. The cobas 4800 HPV test will refer fewer women to colposcopy than
automatic referral of all women with ASC-US. It will also distinguish women infected with
HPV16 or HPV18 from those infected with other HR HPV genotypes, although this feature is
not yet included in clinical guidelines for the management of women with ASC-US. When the
cobas 4800 HPV was utilized by a diagnostic laboratory, its performance was equivalent to
that of HC2 and show comparable levels of performance including results for women >30 years
old with ASCUS cytology [67]. Gage et al found agreement between Cobas and LA to be very
good, better than that between Cobas and HC2 [68].
The Cervista HPV 16/18 Test (Hologic) is a signal amplification qualitative test based on the
Invader chemistry specifically designed to detect HPV-16 and HPV-18 [69].
6. HPV-DNA genotyping methods
HPV DNA-based genotyping as says, which allow exact determination of several alpha-HPV
types present in a clinical sample, are the largest group of currently available HPV commercial
assays. In contrast to the previously described two groups of commercial HPV assays, the clinical
value of HPV DNA-based genotyping assays has still not been finally determined [70-72].
Currently, HPV genotyping methods are indispensable as research tools for the study of the
natural history, transmission, pathogenesis and prevention of HPV infection. However, it is
highly likely that genotyping methods will also have a role in clinical management in the near
future [70,  73,  74].  As the use of prophylactic  HPV vaccines becomes more widespread,
surveillance for population-level effectiveness will become an increasingly important activity,
which will require the use of a HPV genotyping method. If HPV genotyping is to be used for
diagnostic applications and not just as a research tool, it will require standardized and validat‐
ed methods for the specific detection and identification of a defined spectrum of HPV types.
Although DNA sequencing is still considered to be the ‘gold standard’ for HPV genotyping,
it is costly, time-consuming and difficult to apply in routine diagnostic settings. Thus, in daily
practice, the majority of laboratories use nonsequencing based methods for HPV genotyping,
However the next generation sequencing can be implemented in the HPV detection [75]. This
methodology also provides a tumor genomic copy number karyogram, and in the samples
analyzed here, a lower level of chromosome instability was detected in HPV-positive tumors
compared to HPV-negative tumors, as observed in previous studies. Thus, the use of next-
generation sequencing for the detection of HPV provides a multiplicity of data with clinical
significance in a single test.
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The most frequently used HPV genotyping assays today utilize the principle of reverse line-
blot (RLB) hybridization. In these assays a fragment of the HPV genome is first PCR-amplified
using biotinylated HPV-specific primers and the resulting amplicons are then denatured and
hybridized with HPV-specific oligonucleotide probes immobilized as parallel lines on nylon or
a nitrocellulose membrane strip. After hybridization, streptavidin-conjugated alkaline phospha‐
tase or horseradish peroxidase is added, which binds to any biotinylated hybrid previously
formed. Incubation with chromogenic substrates (e.g., BCIP/NBT for alkaline phosphatase)
yields a colored precipitate at the probe positions where hybridization occurs. The genotyping
strip is then read and interpreted visually by comparing the pattern of HPV-positive probes to
the test reference guide for each of the targeted HPV types. In addition to the in-house GP5+/
GP6+ RLB Genotyping Assay which has been used in several important HPV trials [76, 77].
INNO-LiPA HPV Genotyping is one of the most widely used HPV genotyping tests. Several
versions of this assay have been developed. In all versions, amplification of a 65 bp region of the
HPV L1 gene using biotinylated SPF10 primers is followed by hybridization of the resulting
amplicons with 17–28 (depending on the assay version) HPV-specific oligonucleotide probes
immobilized on a nitrocellulose strip [78]. An evaluation of INNO-LiPA Extra, performed on 70
HC2-positive samples, showed comparable genotyping results to the digene HPV Genotyping
RH Test RUO (digene RH Test; Qiagen) and a significantly higher sensitivity of INNO-LiPA Extra
for the detection of multiple infections [79]. Recently is described this method with realtime PCR
[80]. The Linear Array HPV Genotyping Test (Linear Array) is one of the most commonly used
HPV genotyping assays, which combines PCR amplification and reverse line-blot hybridiza‐
tion for the identification of 36 alpha-HPV types. Linear Array is based on the co-amplification
of a 450 bp region of the HPV L1 gene and a 268 bp region of the human β-globin gene, using
biotinylated primer sets PGM09/PGMY11 and PC04/GH20 [81]. Steinau et al [82] compared the
performance of three line blot assays (LBAs), the Linear Array HPV genotyping assay (LA)
(Roche Diagnostics), INNO-LiPA HPV Genotyping Extra (LiPA) (Innogenetics), and the reverse
hybridization assay (RH) (Qiagen). Although the assays had good concordance in the clinical
samples, the greater accuracy and specificity in the plasmid panel suggest that LA has an
advantage for internationally comparable genotyping studies.
Similar to reverse line-blot assays, microarray-based HPV genotyping assays also employ the
principle of reverse hybridization. Following PCR amplification of a fragment of a viral genome
with HPV-specific primers, the resulting amplicons are denatured and hybridized with a number
of HPV-specific oligonucleotide probes attached on the surface of an insoluble supporter or DNA
chip (also known as microchip, biochip and gene chip). DNA chips can consist of one to several
DNA microarrays, thus enabling simultaneous analysis of multiple samples in a single experi‐
ment. After hybridization, fluorescence light from the bound PCR amplicon is detected by
excitation with monochromatic light. Currently, laser scanners are used for the highly sensi‐
tive  fluorescence  microarray  readout  systems.  The  fluorescence  label  of  the  hybridizing
amplicons can be introduced during PCR and/or during the hybridization step. Some of the
microarray-based HPV genotyping tests utilize the principle of chromogenic precipitation
instead of fluorescence detection. The PapilloCheck HPV-Screening Test (PapilloCheck; Greiner
Bio-One GmbH, Frickenhausen, Germany) is currently one of the two most frequently used PCR-
microarray-based assays. The assay allows identification of 24 alpha-HPV types. [83]. Clart HPV
2 – papillomavirus clinical arrays (Clart HPV 2; Genomica, Coslada, Spain) combine PCR
amplification and an oligonucleotide microarray-based detection system for the identification
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of 35 alpha-HPVs. The assay consists of pre-aliquoted, ready to use amplification mix tubes and
allows amplification of a 450 bp region of the HPV L1 gene together with an internal control
template and the human CFTR gene using three different sets of biotinylated primers [84].
The suspension array that uses bead-based xMAP or Luminex technology is based on the use
of polystyrene beads with a diameter of 5.6 µm, which are internally dyed with various ratios
of two spectrally distinct fluorophores (red and infrared). Different bead sets with specific
absorption spectra can be mixed and used for the multiplexed detection of different analytes;
currently, an array of 100 bead sets (bead mix) can be generated. For HPV genotyping purposes,
each bead set in the bead mix is usually coupled to a single oligonucleotide probe specific for
one HPV type. HPV genotyping is done by reverse hybridization technique using biotinylated
PCR amplicons. After denaturation and hybridization of target HPV sequences to the bead-
bound probes, labeling of the hybridized biotinylated amplicons is done using R-phycoery‐
thrin-labeled streptavidin, serving as a reporter fluorophore. The bead sets are then read and
analyzed on a Luminex analyzer; the HPV types are discerned according to the unique bead
signature, whereas the presence of specific PCR amplicons is determined by R-phycoerythrin
fluorescence. The Luminex readouts are expressed as the median fluorescent intensity of the
reporter fluorescence for each HPV type. Positivity for the relevant types is calculated from
the median fluorescent intensity over a defined threshold level, and can provide a semi-
quantitative numerical output. Several in-house genotyping protocols based on xMAP
technology have been developed in the last 5 years [85-91]; some of them are considered to be
the most sensitive HPV detection methods currently available [85]. In addition, at least two
commercial assays based on this technology are available at present.
Gel electrophoresis-based HPV genotyping assays utilize general primer-mediated PCR, type-
specific or group-specific PCR, to screen for a broad spectrum of HPVs, followed by agarose
gel electrophoresis. Restriction fragment length polymorphism (RFLP) is consequently applied
to identify HPV type-specific restriction patterns. In addition to several in-house genotyping
protocols based on RFLP, one commercial assay based on this technology is currently available.
Yi et al [92] report the development of a highly sensitive, highly automated assay based on the
MALDI-TOF-MS platform for the detection and individual genotyping of 14 different HR-HPV
types. The use of the MassARRAY technique and combination of automated DNA extraction/
PCR pipetting procedures increased the detection throughput, which consequently decreased
the cost per case of the assay. Now we can deal with 3,000 samples within 2 working days, and
the current total cost per sample is about $2 (US). The MS HPV genotyping assay is potentially
suitable for routine HPV detection, especially in large-scale cervical cancer screening programs
owing to its high throughput and low cost per case. Proper population-based clinical validation
is needed to establish the clinical relevance of this highly analytically sensitive assay.
7. HPV E6/E7 mRNA screening methods
Several recent studies have clearly shown that testing for HPV mRNA instead of HPV DNA can
be clinically useful [70, 93, 94]. The most relevant transcripts for diagnostic purposes are those
encoding viral oncoproteins E6 and E7. The detection of viral mRNA can be done by reverse
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transcriptase real time PCR [95] or by nucleic acid sequence-based amplification (NASBA). For
the latter,  three commercially available assays that detect E6/E7 transcripts are currently
available. PreTect HPV-Proofer (HPV-Proofer; NorChip, Klokkarstua, Norway) is an assay
based on NASBA technology, which allows qualitative determination of E6/E7 mRNA tran‐
scripts of the five most frequently identified hr-HPV types in cervical cancer worldwide: HPV-16,
HPV-18, HPV-31, HPV-33 and HPV-45 [96]. The NucliSENS EasyQ HPV V1 assay (NucliS‐
ENS; bioMérieux) was launched in 2007 and is based on the original HPV-Proofer assay, except
for the proprietary hardware platform and the software for NASBA measurements and data
analysis [97]. APTIMA HPV Assay (APTIMA; Gen-Probe, San Diego, CA, USA) is a transcription-
mediated amplification-based assay, which allows the detection of E6/E7 mRNA transcripts of
14 HPV types: HPV-16, HPV-18, HPV-31, HPV-33, HPV-35, HPV-39, HPV-45, HPV-51, HPV-52,
HPV-56, HPV-58, HPV-59, HPV-66 and HPV-68. The assay generates a qualitative result for the
presence/absence of 14 targeted HPVs and does not allow the exact determination of HPV type(s)
present in a clinical specimen [98]. APTIMA yielded similar sensitivity for CIN2+ compared with
hc2, Amplicor and Linear Array (95.2 vs 99.6%, 98.9% and 98.2%, respectively), but a significant‐
ly higher specificity (42.2 vs 28.4%, 21.7% and 32.8%, respectively) [55]. In a comparative
evaluation of APTIMA and hc2 on PreservCyt specimens collected from 800 women referred to
colposcopy, APTIMA showed comparable sensitivity to hc2 for the detection of CIN2+ (91 vs
95%), as well as CIN3+ (98 vs 99%), but had higher clinical specificity (>55 vs 47% for CIN2+; 53
vs 44% for CIN3+) [99]. APTIMA had the best sensitivity/specificity balance measured by AUC
(area under ROC curve) comparison test (significant for CIN2+), and the colposcopy referral rate
(9.2%) comparable to that of liquid citology (8.7%) [100].
8. In situ hybridization metods
In situ hybridization (ISH) is the only molecular method allowing reliable detection and
identification of HPVs in topographical relation to their pathological lesions. Unlike other
molecular methods, in ISH the whole HPV detection procedure occurs within the nuclei of
infected cells and not on solid supports or in solutions. The result of the hybridization reaction
is evaluated microscopically and the appearance of an appropriate precipitate within the nuclei
of epithelial cells is indicative of the presence of HPVs in the specimen being tested. In addition,
the physical state of the virus can be evaluated by the presence of punctuate signals for
integrated virus and diffuse signals for episomal virus. Although commercially available HPV
assays based on ISH have been validated technically, they are insufficiently clinically validat‐
ed. In addition, current ISH-based assays are considered by many experts in the field to be too
laborious and to have insufficient clinical sensitivity to be used in routine screening [52].
9. Progression markers
9.1. HPV viral load
HPV viral load is a product of the number of cells infected and number of viruses per infected
cell and is therefore influenced by two main factors: (i) the extent of an HPV infection on the
Human Papillomavirus and Related Diseases – From Bench to Bedside A Diagnostic and Preventive Perspective68
cervical surface and (ii) the level of viral production in the area of infection. Viral load has been
suggested to be a potential biomarker for cervical intraepithelial neoplasia grade 2 (CIN2) or
greater, but currently there is no consistent evidence that a one-time measurement of viral load
is a useful marker of prevalent disease or disease progression [101]. A widespread productive
infection might be associated with high viral load, while a small incipient CIN3 with low-level
virus production might be associated with low viral load. Furthermore, viral load in a
cytological sample is subject to sampling variation in which there are varying proportions of
lesional cells, normal epithelial cells, inflammatory exudate, and blood. A further complication
in using viral load to predict neoplasia of CIN2 or greater is the high prevalence of multiple
carcinogenic HPV infections detected in cervical samples. The current paradigm is that cervical
lesions clonally expand following infection with one specific genotype (one virus-one lesion
concept). On the cervical surface, multiple independent infections or lesions may occur that
are caused by different genotypes. Without specific genotyping conducted in situ, assigning a
causal HPV genotype to a specific lesion can only be based on assumptions [102]. HPV16 is
the only genotype for which there is some indication that viral load may predict viral persis‐
tence and progression to precancer [103-105].
Quantitating HPV viral load seems to be a rational strategy of identifying women at risk for
persistent HPV infection and progression to high-grade dysplasia. Accordingly, a high viral
load could represent many cells with few virions each or a few cells containing many virions.
An inaccurate description of the viral biology and the possible implications for the host could
result from this discrepancy. Recently, studies have focused on longitudinal observations of
viral load to predict viral clearance or lesion progression [106, 107]. Initial data indicate that
repeated measurements can improve prediction of persistence or clearance, but these data are,
so far, limited to HPV16 only. Although signal intensities from HC2 or various endpoint PCR-
based assays have been proposed and partly used as surrogates for viral load, these approaches
have limitations [108, 109]. HC2 only gives aggregate signal strength for a pool of 13 carcino‐
genic types, and commercial genotyping assays, such as the Roche Linear Array (LA) or
Innogenetics InnoLiPA (line probe assay), do not formally report quantitative results. Over‐
estimation of the presence of oncogenic HPV may result. Despite these caveats, the develop‐
ment of HPV viral load assays that may reliably be used as an adjunct screening tool to identify
women at increased risk of progression to CIN 2+ and cervical cancer remains a promising tool
in cervical cancer screening. Recently, Wentzensen et al [110] measuring signal intensities on
LA HPV genotyping strips provides quantitative information comparable to viral load
measurements based on Q-PCR. This approach offers the potential for viral load assessment
for 37 types in parallel, simplifying conducting repeated measurements of viral load in
epidemiologic studies and addressing the problems of multiple HPV genotype infections in
studies of HPV load.
Screening for HPV integration into the host genome is a subcategory of HPV diagnostics. HPV
integration is a key molecular event in the transition from an innocuous HPV infection to one
that has oncogenic potential. Human papilloma virus integration results in increased expres‐
sion of the viral E6 and E7 proteins. Increased expression of these proteins ultimately results
in the disruption of host cell proteins, p53 and retinoblastoma protein [111]. Tests that detect
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the integration of HPV into the host cell and corresponding risk of CIN 2+ or cancer are in
development, and may provide a useful way of screening women at risk for cervical cancer.
Studies have shown that viral integrants are detected in 100% of HPV-18-positive and 70–80%
of HPV-16-positive cases of cervical carcinoma [112, 113]. A smaller subset of HSIL (15%) and
0% of LSIL contain transcriptionally active viral integrants [111].
Detection of p16(INK4a) correlates tightly with viral integration. In a normal cell, p16 blocks
cyclindependent kinases (CDK) 4/6. Increased expression of the E6 and E7 oncogenes disrupt
cell–cycle regulation, resulting in cell–cycle progression. In the normal cell, cell–cycle pro‐
gression is activated by CDK 4/6 and in part regulated by p16. Because in HPV-transformed
cells, cell–cycle activation is caused by E7 and not by CDK 4/6, p16 has no effect on the cell–
cycle activation. Increased expression of p16 in cells driven by viral oncogene-mediated cell-
cycle dysregulation can be detected through cellular immunostaining [114].
Because the correlation between HPV mRNA and high-grade dysplasia is a biologically
plausible biomarker of risk, HPV mRNA detection may improve the specificity in the evalu‐
ation of women with ASCUS and LSIL Pap smears [115]. Many women have lesions that will
not progress to CIN3 or invasive cancer, and these women currently present a treatment
dilemma. No reliable methods can identify those lesions that are likely to regress. As a result,
these women are monitored with serial colposcopic examinations at great expense to patients
and the healthcare community. Detection and quantification of mRNA transcripts in these
women may further refine current broad-spectrum, high-risk HPV DNA typing by allowing
clinicians to know whether or not the virus is actively replicating E6 and E7 oncogenes.
Messenger RNA transcript assays show great promise for being able to stratify the risk of
progression to high-grade dysplasia in women with abnormal cytology.
The E6 strip test is also a biomarker that indicates viral integration. Schweizer et al. [116]
evaluated the correlation of the HPV E6 test (Arbor Vita Corporation, Fremont, CA), which
takes an hour to carry out and detects the HPV-E6 oncoprotein of HPV types 16,18 and 45,
with detection of oncogenic HPV DNA in cytologic samples.
9.2. Screening methods identifying epigenetic changes
Many genes are currently being evaluated as potential methylation biomarkers for cervical
cancer, but assay reliability for these methylation markers is highly variable. Within the human
genome, methylation of cytosines in the CpG dinucleotides (also known as CpG sites) clustered
into islands associated with transcriptional promoters is an important cellular mechanism to
regulate gene expression. Methylation of HPV DNA by infected cells may alter the expression
patterns of viral genes that are relevant for infection and transformation [117]. Increased
methylation of CpG sites within the HPV16 genome before diagnosis and at the time of
diagnosis was associated with cervical precancer [118]. Some promising candidate genes
include DAPK1, CADM1, and RARB [119].
Another area of biomarker research is in the use of telomerase RNA component (TERC)
identification by fluorescence in-situ hybridisation. Most cervical cancers have an extra copy
of the long arm of chromosome 3, and consequently show amplification of TERC (present on
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chromosome band 3q26), which seems to play a key role in progression from low-grade
dysplasia to cancer [120]. Many studies indicate that TERC identification may become a useful
screening tool for cervical cancer. A prospective study by Andersson et al. [121] found a
correlation between increasing TERC detection in cytology specimens and higher grade of
dysplasia. They showed that progression to cervical cancer is never seen without TERC
amplification and that, conversely, specimens without extra copies of TERC were likely to
undergo spontaneous regression of HPV infection.
Other biomarkers under early evaluation for cervical cancer screening include CDC6 and
MCM5. These proteins are present in normal cells only during the activation of the cell cycle
and help form prereplicative DNA complexes during the G1 phase. They are absent from the
cell during quiescence and differentiation. Dysplastic cells have unregulated cell cycles and,
as a result, CDC6 and MCM5 reflect cell proliferation [122]. Studies indicate that CDC6 may
be a biomarker of high-grade and invasive lesions of the cervix, with limited use in low-grade
dysplasia. MCM5 seems to be a biomarker that is expressed independent of high-risk HPV
infection, and may in the future serve as a useful marker for both HPV dependent and HPV-
independent cervical dysplasia [122].
General markers of cell proliferation like MIB-1, MCMs or ProEx C, and surrogate markers of
high risk HPV infection like p16 INK4A have shown promising results. Other potential
candidates need to be tested until we find an ideal combination. Following the example of the
p16 INK4A /MIB-1 dual staining combination and the MCM2/TOP2A combination (ProEx C),
combinations are often superior to any single marker and should be tested. A critical deter‐
minant for the success of future investigations will be the standardization of sample prepara‐
tion and interpretation. Furthermore, before reaching the point of routine application, this
ideal ‘biomolecular’ or ‘immune-enhanced Papanicolaou test’ needs to be evaluated in large
prospective clinical trials with appropriate colposcopic, histological, and clinical endpoints as
well as adequate follow-up [123].
9.3. Screening methods for detect HPV infection
In order to facilitate the acceptance of novel HPV assays, mainly for cervical screening
purposes, several recommendations have recently been published [70, 124, 125]. Meijer et al.
proposed that before a new HPV assay can be used for cervical screening purposes, it should
demonstrate at least similar if not better clinical characteristics (sensitivity, specificity,
reproducibility, and so on) for the detection of CIN2+ as hc2 [125]. Other experts believe that
large-scale clinical trials, with an assessment of prospective disease outcomes, are required to
validate any proposed HPV screening test and that cross-sectional comparisons of new HPV
assay to HC2 using several hundred specimens are not an acceptable form of assay validation
[70]. Stoler et al. recently proposed that any novel HPV assay aiming to be used for cervical
screening should have a clinical sensitivity of 92% ± 3% for CIN3+ to render a high NPV or the
capacity to predict the future detection of a CIN3+ outcome that might occur during a
recommended screening interval [124]. The HPV assay aiming to be used for cervical screening
should also have a clinical specificity of at least 85% to achieve an adequate PPV for CIN3. The
common idea behind all proposed recommendations is that a clinically useful HPV assay
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should achieve an optimal balance between clinical sensitivity and clinical specificity for
detection of CIN2+/CIN3+ in order to minimize redundant or excessive follow-up procedures
for hr-HPV-positive women with transient hr-HPV infections and/or without cervical lesions.
Thus, as an example, a HPV assay with very high analytical sensitivity can yield a large number
of clinically insignificant positive results, which will cause unnecessary clinical follow-up,
unnecessary diagnostic procedures and unnecessary treatment of healthy women [126].
In forthcoming years, self-sampling may become increasingly important in cervical screening
since self-collection for HPV testing (HPV self-sampling) has shown to persuade a subset of
non-attendees to participate [127-129]. Targeting non-attendees is important, because they are
at higher risk of developing cervical cancer. Additionally, self-sampling may make cervical
screening accessible to women in developing regions [130].
An accurate and internationally comparable HPV DNA detection and genotyping methodol‐
ogy is an essential component both in the evaluation of HPV vaccines and in the effective
implementation and monitoring of HPV vaccination programs. Genotyping assays used today
differ in their analytical performance with regard to type-specific sensitivity and specificity
[131]. The evaluation of assay performance needs to be performed in a standardized manner,
where different assay performances can be evaluated and results can be compared against a
known and accepted standard over time.
In 2008, the WHO HPV LabNet conducted a proficiency study based on HPV DNA plasmids
containing the genomes from 14 oncogenic HPV types and 2 benign HPV types and open for
participation to laboratories worldwide [132]. This study demonstrated that it is possible to
perform global proficiency studies with unitage traceable to ISs based on plasmid DNA and
that such studies can provide an overview of the status of the HPV detection and typing
methodology worldwide. More recently, based on a proficiency panel composed of the same
HPV DNA plasmid material used in 2008, with the amount of DNA titrated in amounts
traceable to the IS. The use of the same panel material allowed a reproducible, standardized
evaluation of assay sensitivity over time. Specificity was defined as absence of incorrect typing.
The sample preprocessing was evaluated with extraction controls of cervical cancer cell lines.
The panel was distributed to 105 laboratories worldwide and analyzed using a range of HPV
DNA typing assays in a blinded manner [133]. Among laboratories that used the same assay
in both years, 27% were proficient in 2008, whereas 30% were proficient in 2010. They also saw
a strong trend toward increased sensitivity of assays. For example, among the laboratories
using the same assay in 2008 and 2010, 50 IU of HPV-16 could be detected by all (100%)
laboratories in 2010, whereas 86% of laboratories could detect 50 IU of HPV-16 in 2008.
However, for several laboratories, the increased sensitivity was accompanied by increased
amounts of false-positive results, resulting in nonproficiency, suggesting that recommenda‐
tions for HPV laboratory testing include an increased emphasis on the use of negative controls
in the assays.
The demands on sensitivity of HPV typing assays vary depending on the purpose of the
testing. The WHO HPV LabNet proficiency panels are designed to evaluate the performance
of HPV typing tests used in HPV vaccinology and HPV surveillance. In vaccinology, high
analytical sensitivity is needed, as failure to detect prevalent infections at trial entry may result
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in false vaccine failures in vaccination trials. It should be noted that the HPV tests used in
cervical cancer screening programs have different requirements for evaluation, since for that
purpose, only HPV infections associated with high-grade cervical intraepithelial neoplasia or
cancer and not those transient HPV infections that do not give rise to clinically meaningful
disease are relevant. Since the latter are characterized by low viral loads, HPV screening assays
do not have demands on analytical sensitivity that are as high [125].
10. Measuring the immune response to vaccine
HPV serology is an essential technology for both HPV vaccinology and HPV epidemiology.
Definitions of HPV-naïve subjects eligible for HPV vaccination trials include seronegativity
for HPV. Immunogenicity of HPV vaccines has been used to bridge results from efficacy trials
in adolescents to children and to evaluate different batches of HPV vaccines. Antibody
measurements are also important in vaccinology research, e.g. for characterizing the immune
response with respect to studies of seroconversion and antibody increases, cross-reactions,
immune memory and immune persistence as well as kinetics of antibody responses and
establishment of correlates of protection. Finally, HPV seroepidemiology is also useful for
understanding the epidemiology of HPV infections in populations to be targeted by HPV
vaccination programs. The lack of a standardized assay to measure HPV antibody levels has
hindered both epidemiological studies of HPV infection and comparison of results from
different HPV vaccine trials [134]. WHO Guidelines for HPV vaccines suggest that “initial
assessment of immune responses to HPV VLP vaccines should be based on measurement of
neutralizing antibodies in serum”. The available data [134-136] suggest that neutralizing and
ELISA antibody titres are usually highly correlated when the ELISA antigen target is confor‐
mationally intact VLPs. Due to the complexity and labour-intensiveness of neutralization
assays, VLP-based ELISAs have been preferred in large epidemiological studies. E.g., a study
of HPV seroprevalences was conducted by measuring HPV 16 antibodies with an HPV16 L1
VLP-based ELISA to estimate the public-health impact of HPV vaccination strategies [137].
WHO has been coordinating work to develop standard assays that will help in assessing
vaccine quality and monitoring impact after vaccination [138]. In 2006, WHO established a
global HPV laboratory network (LabNet) with a main focus being the harmonization and
standardization of laboratory testing procedures to support consistent laboratory evaluation
of regional disease burden and monitoring of the performance of HPV vaccines. At a WHO
consultation in January 2008, a group of experts recommended that the HPV LabNet should
develop or identify standardized assays for general use and that efforts towards standardiza‐
tion on VLP-ELISA should be a high priority of the WHO HPV LabNet [139]. Following the
recommendation, the WHO HPV LabNet launched a serology standardization program
encompassing: (i) an international collaborative study to evaluate and refine a direct HPV 16
VLP-ELISA suggested Standard Operating Procedure (SOP), (ii) an international request for
donations of VLPs to be used as international reference reagents for serology, followed by
characterization and selection of optimal reagents, and (iii) an international collaborative
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proficiency study on HPV 16 serology, where participating laboratories used the same
standardized SOP and the same VLP reference reagent [140].
Serologic assays for the evaluation of HPV vaccine responses are currently limited to an
enzyme-linked immunosorbent assay (ELISA) [141], three multiplex assay systems [142-144],
and a pseudovirus neutralization assay [145], and emerging data suggest that each system has
some utility for characterizing HPV vaccine antibody specificity [136, 146]. Protection against
vaccine types is thought to be mediated by neutralizing antibodies [147], and while the
mechanism of vaccine-induced cross-protection is uncertain, the measurement of antibodies
against nonvaccine types may be useful as a potential correlate or surrogate of cross-protection
[148, 149]. Recently, Bissett et al [150] obtain a sera panel. These plasma pools could be useful
as reference reagents. They are currently available as 250-µl aliquots of liquid plasma archived
at −80°C and can be obtained from the National Institute for Biological Standards and Control.
Type-specific L1 VLP-antibodies reach maximum titres at month 7, i.e. 1 month after administra‐
tion of the third dose. Titres decline until month 24 and remain rather stable thereafter [151, 152].
At 3 years, antibody titres remain two- to 20-fold higher than in placebo controls [152]. Com‐
plete protection against HPV16 associated CIN lesions was observed over the whole follow-
up duration of two Phase IIb trials: 6 years for the monovalent HPV16 vaccine, 5 5 years for the
bivalent HPV16/18 vaccine [153, 154] and 4 years for the quadrivalent vaccine. Follow-up is
continuing, and continued protection against HPV 16/18-associated disease end-points has been
shown for the entire available observation time, even when specific antibody titres fall.
HPV infection is the most prevalent soon after sexual debut of a girl [155]. The current HPV
vaccines, being prophylactic in nature, should be used before exposure of girls to HPV
infection. National mass vaccination programs targeting adolescent girls between 12 and 17
years of age are available in most of the developed countries. The vaccine coverage varies
greatly between countries, but school-based schemes have thus far demonstrated the highest
coverage rate of 80% or higher [1, 156-158]. Australia is the first country to implement a school-
based mass vaccination program with Gardasil in April 2007 and, within 3 years, has already
witnessed a reduced incidence of high-grade abnormalities (HGAs) among women below 18
years of age [1].
High coverage rates of adolescent vaccination with rubella and hepatitis B suggest that, with
appropriate parental and public education, adequate HPV vaccine uptake rate of 50% or more
is achievable. This coverage rate is critical for mass vaccination to attain cost-effectiveness as
a public measure in controlling cervical cancer burden [159]. It will also remove the imbalance
in accessing screening and effectively diminish the unequal distribution of cervical cancer
burden among women in the metropolitan and rural areas, among women of different ethnic
groups, and among women of various socio-economic status in developed countries. Adoles‐
cent HPV infection protects women from the first exposure to HPV infection at sexual debut
and abolishes the opportunity for latent infection to occur with a resultant reduction of cervical
cancer in old age. The current HPV vaccines induce very high levels of anti-HPV-16 and anti-
HPV-18 antibody levels to sustain protection from infection by these aggressive oncogenic
HPV subtypes for at least 20 years to cover the average age period of sexual debut [160].
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A measure to address the concern of vaccination efficacy for older women is to consider
vaccinating women at middle ages. Undoubtedly, vaccinating mid-adult women misses the
most at-risk period of a woman's life for contracting HPV infection at sexual debut. It is,
however, shown that one must not dismiss lightly a mid-adult woman who wants to take the
vaccination to prevent new or repeat HPV infection [161]. The vaccines have been shown to
be immunogenic in adult women and significant prevention of persistent HPV-16 and HPV-18
infection has been demonstrated in a randomized control trial [162]. The effectiveness of the
vaccines among these women in reducing the incidence of HGAs is being awaited with great
interest. The shifting burden of cervical cancer to the young and the old in the screened
population should disappear in the HPV vaccination era [163].
Immunization of boys with VLPs elicits a serum immune response similar to that in girls.
Because genital HPV infection is sexually transmitted, immunization of men may help to
prevent infection of women. Modeling studies on herd immunity, i.e. indirect protection of
those who remain susceptible, owing to a reduced prevalence of infections in the risk group
for disease, have been published [164]. The utility of immunization of males depends upon
the assumed population coverage of vaccination, with successively smaller additional benefits
seen in scenarios with high population coverage [165]. Modeling of programs with high
population coverage (90%) have found that addition of male vaccination gives a more rapid
infection control and have suggested that both sex vaccination programs may be required to
achieve an ultimate eradication of the infection [137].
Limitations of the current HPV vaccines include the need for multiple parenteral doses, the
lack of protection against some HPV types that cause cervical cancer, and a relatively high cost.
The opportunity to overcome 1 or more of these limitations provides a rationale for developing
candidate second-generation vaccines. Low-cost second-generation vaccines that could induce
long-term protective immunity with fewer doses would be especially attractive for the
developing world. Vaccines with activity against a broader range of the HPV types that cause
cervical cancer could increase their effectiveness throughout the world, and Merck has
indicated that a nonavalent (9 HPV targets) VLP vaccine is currently in clinical trials [166]. If
successful, such a vaccine might reduce the frequency of potentially oncogenic infections to a
degree that would permit a drastic reduction in cervical cancer screening, which accounts for
most of the cost of HPV-associated disease in developed countries [167].
11. Future prospects and conclusions
HPV differs from most other vaccine-preventable diseases in that the major diseases to be
prevented occur many decades after infection. Whereas clinical trials have documented
prevention of infection and intermediate disease end-points (condylomas and precancers),
surveillance following vaccine implementation will be required to document the expected
gains in cancer prevention if there is appropriate population coverage. Surveillance will also
provide data to indicate if type replacement or escape mutants occur. Other important tasks
for the HPV surveillance include monitoring of the duration of protection, long-term safety
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and actual effects on health-care cost consumption. Monitoring the impact of vaccination on
type-specific infection could be important as it is the earliest change that could be anticipated,
and failure to detect protection from infection will indicate failure to impact cancer in the
decades that follow and allow appropriate changes in strategy to be introduced. As countries
differ in their health-care priorities and infrastructure as well as in their incidence and
prevalence of various HPV infections, their HPV vaccination strategies are also likely to differ
[168]. As has been mentioned, the waning in the levels of HPV antibodies post-vaccination
appears to plateau after 5 years. It is not known whether waning of HPV antibody levels in
the longer term will require a vaccine booster. In addition, antibody correlates of protection
have not been defined because there have so far been almost no cases of vaccination failure. If
a reliable immunological correlate of protection can be identified, this will help in assessing
the requirement for booster vaccinations and greatly facilitate the evaluation of second-
generation vaccines.
As the type-specific prevalence of HPV infection is very high in young sexually active
populations, the effect of a successful HPV vaccination programme should be detected quite
rapidly by sentinel surveillance in these populations. The specific design of these sentinel
studies will vary, but selecting clinics offering sexual counselling may be more efficient than
school-based sampling. Reduction in the prevalence of types targeted by the vaccines as well
as no increase in the prevalence of non-vaccine types are important end-points. Baseline data
are needed to establish prevaccine prevalence as well as to determine the sample size required
to observe impact beyond confidence intervals of sampling and testing errors. It is imperative
that all HPV DNA prevalence surveys are performed using testing methodology that has been
subjected to an international quality assurance, as comparability of data between countries or
even before versus after will otherwise not be possible.
Screening remains an important strategy in cervical cancer control in the HPV vaccination era.
Women who have received HPV vaccination should continue regular screening, as cases of
HGAs and invasive cervical cancer among vaccinated women have been reported [169]. There
is also a concern whether the protective effect of adolescent vaccination has an impact on the
incidence of cervical cancer when the vaccinated cohort reaches older age. It is reassuring to
see evidence that, in well informed communities, there appears to be no change in women's
attitude toward continual screening [170]. Furthermore, screening remains the only effective
method for cervical cancer prevention for women who opt out of vaccination. However,
reduction in the incidence of HGAs in young women following adolescent mass HPV
vaccination supports a strategy to delay screening to a later age than the current practice of
starting screening once the girl becomes sexually active.
Evidence from meta-analysis has overwhelmingly demonstrated the superiority in sensitivity
of HPV DNA test over cytology in cervical cancer screening. Indeed, retrospective analysis of
invasive cervical cancer tissues in well screened populations showed that more than 80% of
cases were related to HPV-16 or HPV-18 [171]. With elimination of HPV-16 and HPV-18 with
mass vaccination, the remaining oncogenic subtypes of HPV, which have low neoplastic
transformation rates, should significantly lower the incidence of HGAs. The sensitivity and
positive predictive value of cytologic screening will be further compromised [172]. The
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recently available HPV-16-specific and HPV-18-specific screening technology further enhan‐
ces the technical advances that makes the HPV DNA screening test even more attractive in the
vaccination era than before. The high sensitivity of the HPV DNA test should allow the
screening interval to be increased to a longer period [173].
The reduction in background risk of cervical cancer by elimination of the most important HPV
types will affect cost-effectiveness of screening programs and may, in the long term, allow
increasing screening intervals. Co-ordinated quality assurance/monitoring of HPV vaccination
and cervical screening is advisable for finding the most efficient strategies for cervical cancer
control. Data on vaccination coverage will be essential for every country performing HPV
vaccinations. HPV vaccination registries are preferable, but sales statistics and serosurveys
may be alternatives.
For rapid assessment of vaccine program efficacy, the continuous monitoring of which HPV
types are spreading in the population will become necessary for early monitoring of ‘type
replacement’ phenomena, inappropriate vaccination strategies or other reasons for vaccination
failure. Surveys in sexually active teenagers and/or in younger participants of cervical
screening programs should be contemplated.
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